Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection

BACKGROUND: The COVER trial evaluated whether nitazoxanide or sofosbuvir/daclatasvir could lower the risk of SARS-CoV-2 infection. Nitazoxanide was selected given its favourable pharmacokinetics and in vitro antiviral effects against SARS-CoV-2. Sofosbuvir/daclatasvir had shown favourable results in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokhela, Simiso, Bosch, Bronwyn, Hill, Andrew, Simmons, Bryony, Woods, Joana, Johnstone, Hilary, Akpomiemie, Godspower, Ellis, Leah, Owen, Andrew, Casas, Carmen Perez, Venter, Willem Daniel Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384711/
https://www.ncbi.nlm.nih.gov/pubmed/35953881
http://dx.doi.org/10.1093/jac/dkac266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384711/
https://www.ncbi.nlm.nih.gov/pubmed/35953881
http://dx.doi.org/10.1093/jac/dkac266

Ejemplares similares